Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancer

Jia Zhang1, Hongmei Yao2, Ge Song2, Xia Liao2, Yao Xian2, Weimin Li2
1Second Department of Thoracic Surgery, 2Department of Nutrition, The First Affiliated Hospital of Xi’an Jiaotong University, 277# West Yanta Road, Xi’an, Shaanxi 710061, China

Received June 29, 2015; Accepted October 11, 2015; Epub October 15, 2015; Published October 30, 2015

Abstract: It should be urgently better understood of the mechanism that contributes cancer aggressiveness. Epithelial-mesenchymal transition (EMT) plays a fundamental role in tumor progression and metastasis formation by invasion, resistance to cell death and senescence, resistance to chemotherapy and immunotherapy, immune surveillance, immunosuppression and inflammation, confers stem cell properties. Tumor-associated macrophages (TAMs) are key orchestrators and a set of macrophages in tumor microenvironment. They are major players in the connection between inflammation and cancer. TAMs could promote proliferation, invasion and metastasis of tumor cells, stimulate tumor angiogenesis, and inhibit anti-tumor immune response mediated by T cell, followed by promoting tumor progression. Recently, studies showed that TAMs played critical role in the regulation of EMT in cancer, although the underlying mechanism of TAMs-mediated acquisition of EMT has been largely unclear. This review will discuss recent advances in our understanding of the role of TAMs in the regulation of EMT during tumorigenesis and summarize the recent ongoing experimental and pre-clinical TAMs targeted studies.

Keywords: Cancer, tumor-associated macrophages, epithelial-mesenchymal transition

Introduction

Cancer is a major public health problem in the United States and many other parts of the world. A quarter of the deaths in the United States is due to cancer [1]. It is the leading cause of death in developed countries and the second leading cause of death in developing countries [2]. Currently, one third of women and half of men in the United States developed cancer during their lifetime [3]. In the United States, it was estimated that there was 1,660,290 new cancer cases and 580,350 cancer deaths in 2013. The five-year relative survival rate is approximately 65% for all human cancers due to the lack of understanding of the exact mechanism underlying cancer development and progression [1]. Therefore, a better understanding of the mechanism which contributes cancer aggressiveness is urgently needed.

In 1968, Elizabeth Hey first defined the concept of epithelial-mesenchymal transition (EMT). It is an essential embryonic process during which epithelial cells loose contact with their neighbors and gain mesenchymal properties, this could enable them to break through the basement membrane which separates different tissues from the embryo [4]. Later researchers discovered aberrant reactivation of EMT could promote tumor cell migration and invasion by disruption of apical-basal polarity and loss of E-cadherin expression [5-7]. Hence, it will greatly benefit our understanding of tumor migration and invasion that clarifying the regulation of EMT.

Tumor-associated macrophages (TAMs) are key orchestrators and a set of macrophages of the tumor microenvironment [8, 9]. They are major players in the connection between inflammation and cancer [10]. TAMs could promote proliferation, invasion and metastasis of tumor cell, stimulate tumor angiogenesis, and inhibit anti-tumor immune response mediated by T cell, followed by promoting tumor progression [11, 12]. Accumulated evidences have demonstrated that TAMs plays critical role in the regulation of EMT in cancer [13-16]. This review will summa-
rize what is known about TAMs in cancer development and progression and the role of TAMs in the regulation of EMT, so as to get a better understanding of the mechanism that contributes to cancer aggressiveness. Lastly, we will describe potential application of TAMs as targets for the prevention and/or treatment of human cancers in the future.

**Epithelial-mesenchymal transition**

In 1968, Elizabeth Hey first proposed the concept of EMT. It is an essential embryonic process, during which polarized epithelial cells convert to motile mesenchymal cells. The typical characters of this process are loss of cell-cell adhesions and apical-basal polarity in epithelial cells, and the acquisition of migratory and invasive properties [5]. Later researchers discovered aberrant reactivation of EMT could promote tumor cell migration and invasion [5-7]. By suppressing the expression of epithelial markers such as E-cadherin, and by increasing the expression of mesenchymal markers including Vimentin, Slug, Snail, Fibronectin, zinc-finger E-box binding homeobox 1 (ZEB1), ZEB2, and α-smooth muscle actin (SMA), the cells acquire the ability to migrate and invade, which could lead to tumor progression and metastasis [5].

EMT plays a fundamental role in tumor progression and metastasis by invasion, resistance to cell death and senescence, resistance to chemotherapy and immunotherapy, immune surveillance, immunosuppression, and inflammation, and confers stem cell properties [5]. So far, many growth factors, cytokines and cellular signaling pathways have been found in EMT regulating in cancer, including transforming growth factor beta (TGF-β), forkhead box protein M1 (FoxM1), hepatocyte growth factor (HGF), epidermal growth factor factor (EGF), NFκB, Notch, and Wnt [5, 17-19]. Recently, the growing body of literature strongly suggested that TAMs played a critical role in regulation of EMT in cancer [13-16]. Therefore, we will highlight the function of TAMs in the regulation of EMT in human cancers.

**The promotion role of TAMs in cancer**

**The polarization role of TAMs in cancer**

Macrophages can be divided schematically into two main classes in line with the Th1/Th2 dichotomy [10]. They are simplified as either classical ‘M1’ or alternative ‘M2’ [20]. Microbial stimuli such as lipopolysaccharides (LPS) and Th1 cytokines such as interferon gamma (IFN-γ) drive macrophages to the classically activated state. The characters of these cells are increased expression of inflammatory cytokines, chemokines, and reactive nitrogen/oxygen intermediates (RNI/ROI). The functions of these cells including promoting Th1 effector response, anti-microbial ability, protection against various types of bacteria and viruses, and tumoricidal functions. In contrast, Th2 cytokines such as IL-4 and IL-13 drive macrophages to the alternatively activated state [21]. The characters of these cells are increased expression of scavenging receptors and scavenging activity, reduced expression of inflammatory cytokines, and preferentially metabolized arginine to ornithine via arginase. The functions of these cells including anti-inflammatory, the promotion of Th2 response, tissue repairing and remodelling, protection from parasite infection, and tumor promotion. M1- and M2-polarized macrophages have been indicated in tumors [22]. TAMs resemble M2-polarized macrophages [23].

**Origin of TAMs**

The historic description of tissue macrophages is that they are solely derived from bone marrow (BM). However, evidences from recent studies suggest that most tissue macrophages originate from circulating BM monocytes [24]. Evidence indicated macrophages involved in pathogen responses originate from circulating BM monocytes [25]. Evidences from several recent studies demonstrate that most TAM subpopulations derived from the Ly6C+ population of circulating mouse monocytes in primary mouse mammary tumors, grafted tumors and lung metastases [26-28]. It is reported that TAMs are solely derived from BM as the primary source of monocytes in the Lewis lung carcinoma syngeneic transplant model [29].

Various soluble factors have been reported to regulate the origin of macrophages at the molecular level. CSF1 is the master regulator and chemotactic factor of most populations of macrophages whether they are derived from the yolk sac or BM [30]. High CSF1 expression in cancer is associated with poor prognosis; while knocking-out CSF-1 receptor (CSF-1R) in
cancer shows delayed initiation, progression, and metastasis by the depletion of TAMs [12, 31]. Many tumors and their stroma could release abundant CSF-1. Tumors could orchestrate the recruitment and differentiation of BM into TAMs by releasing CSF-1 and other monocyte/macrophage chemoattractants [24]. IL-34, the second ligand for CSF-1R, is reported expressing in breast cancer cells following cytotoxic therapy and is associated with the recruitment of TAMs [32, 33]. In a xenograft model of skin cancer, VEGFA could recruit macrophage progenitors and then differentiate into TAMs in the presence of IL-4, and the lossing of these TAMs inhibited tumor growth, tumor invasion, proliferation and tumor angiogenesis [34]. In the Polyoma Middle T oncoprotein (PYMT) model, the binding of CCL2 to its receptor CCR2 directly mediates the monocyte recruitment to the primary tumor and metastases in the presence of CSF-1 [26, 28, 35]. In human breast cancer models, CCL18 binding to its receptor PITPNM3 mediates TAMs recruitment in collaboration with GM-CSF [13]. In colon cancer models, CCL9 binds to its receptor CCR1 and mediates the immature myeloid cells recruitment [36]. The ablation of these chemokines got in the loss of monocytes and/or TAMs and the inhibition of malignancy.

The origins of TAMs in many cancers is still uncertain. Further study characterizing TAMs in different human cancers and their relationship to the possibly existing different macrophages is now warranted.

Roles of TAMs in cancer initiation and promotion

TAMs are key orchestrators and a set of macrophages of the tumor microenvironement [8, 9]. They are major players in the connection between inflammation and cancer [10]. In 2009, Colotta firstly defined cancer-related inflammation (CRI) as the seventh hallmark of cancer [37]. CRI is one of the ten redefined hallmarks of cancer [38]. The reason why CRI associates with increasing cancer risk is that chronic infection or persistent irritation is often called “smoldering inflammation” [39]. Activated macrophages work in concert with other immune cells in this type of immune response as major players [40]. Evidences show inflammatory microenvironement promote genetic instability within the developing tumor epithelial cells, the infiltrating or resident immune cells in inflammatory microenvironement including macrophages [37]. Studies have demonstrated the essential role for macrophages in promoting tumor progression through NF-kb-induced expression of cytokines such as TNF and IL-6 [41, 42]. Recently, evidences showed TAMs-derived proinflammatory cytokine IL-23 and the Th17 pathway were associated with progression of spontaneous colon cancer [43].

Roles of TAMs in cancer angiogenesis

Tumor and its stromal cells produce different meditators that promote angiogenesis. Growth factors such as VEGF, TGF-β, PDGF and members of the FGF family released from TAMs possess proangiogenic role in many tumors [44-47]. TAMs secrete angiogenic factor thymidine phosphorylase and produce several angiogenesis modulating enzymes including MMP-2, MMP-7, MMP-9, MMP-12, and cyclooxygenase-2 [48-51]. Tie-2 expressing monocytes/macrophages (TEMs) have been reported to possess proangiogenic role in many human and mice tumors [52, 53]. TAMs release many chemokines involved in angiogenic processes such as CXCL12, CCL2, CXCL8, CXCL1, CXCL13, and CCL5 [54, 55]. Hypoxia is a major driver of angiogenesis. The hypoxic areas of the tumor can see the accumulation of macrophages, particularly in necrotic tissue [56]. HIF1α, which is expressed in macrophages, modulates the recruitment of macrophages to hypoxic regions of the tumor. This recruitment is through CCL-2, endothelins and other chemokines [56, 57]. HIF1α regulates the transcription of a large panel of genes associated with angiogenesis at the hypoxic site including VEGF [56, 58]. TAMs are also involved in lymphangiogenesis, and the lymphatic endothelial growth factors secreted by TAMs are associated with peritumoral lymphangiogenesis [59, 60].

Roles of TAMs in cancer invasion and metastasis

Evidences from a study in the PyMT mouse model and in breast cancer cell xenografts show that TAMs are required for tumor cell migration and invasion [61]. The mechanism is that CSF-1 synthesized from tumor cells stimulates TAMs to move and produce EGF, afterward activates migration in the tumor cells [62].
Regulation of EMT by TAMs in cancer

Co-culture of tumor cells with TAMs increases invasiveness of cancer cells through TNF-α dependent MMP induction in TAMs [63, 64]. Evidences from tissue culture experiments show Wnt5a acting through the noncanonical pathway in organoids and TNF-α via NFκB in coculture promote tumor cell invasion [65, 66]. Reduction of the number of TAMs by genetic methods or inhibition of EGF or CSF-1 signaling in wild-type mice bearing mammary tumors reduces the number of circulating tumor cells [67, 68]. TAMs produces the most Urokinase/Plasminogen activator (uPA), and in the PyMT model its loss inhibits metastasis [69]. A CSF1-EGF paracrine loop between TAMs and tumor cells has been implicated in breast cancer cell invasion and intravasation [61]. Evidence show macrophages are essential for malignant progression and metastasis in a spontaneous model of skin carcinoma [70]. An in vivo study indicates high cathepsin activity in TAMs mediates tumor growth, angiogenesis, and invasion in pancreatic cancer [68].

Roles of TAMs in cancer immunoregulation

Macrophages are the major immunoregulatory cells in tumors, and they take great part in immune responses in tumors [12]. In 1988, Fidler first reported that activated macrophages could kill tumor cells and eliminate metastases [71]. Later evidences show activating macrophages by either overexpressing GM-CSF or treating tumors with CpG plus anti-IL-10 could inhibit tumor growth in xenograft models [72, 73]. The characters of these immunoregulatory TAMs are downregulation of IL-12, IL-18, and TLR signaling pathway and upregulation of arginase [74, 75]. This is in agreement with TAMs are M2-polarized population [47]. GM-CSF control TAMs differentiate to trophic TAMs and then apart from immunologically activated ones in the presence of high concentrations of CSF-1 [39, 76]. TAMs could also inhibit cytotoxic T cell responses. The production of IL-10 from TAMs can induce the expression of costimulatory molecule programmed death ligand (PD) L1 in monocytes, these monocytes could inhibit cytotoxic T cell responses [77]. In human ovarian cancers the production of CCL22 from TAMs regulates the influx of regulatory T cells that inhibit cytotoxic T cell responses [78]. TAMs in mammary tumor xenografts cytotoxic T cell responses by the synthesis of PGE2 and TGF-β [79]. These facts indicate the immunoregulation roles of TAMs in cancer (Table 1).

Roles of TAMs in regulating cancer EMT

EMT plays a fundamental role in tumor progression and metastasis formation, clarifying the regulation of EMT will greatly benefit our understanding of tumor migration and invasion. Increasing evidences have revealed that many growth factors, cytokines and cellular signaling pathways play great roles in initiation and execution of EMT, including TGF-β, FoxM1, HGF, EGF, NFκB, Notch, Snail, ZEB1, ZEB2, Twist1, KLF4, KLF8, Sox9 and Wnt [5, 17-19, 80]. Accumulated evidences have demonstrated that TAMs played critical role in the regulation of EMT in cancers [13-16]. In the following sections, we will discuss the crosstalk between TAMs and selected signaling pathways, including which play critical roles in EMT.

Crosstalk between TAMs and NFκB

NFκB is a major inflammation mediator and an oncogenic key transcription factor, it is activated in breast cancer and its activation leads to direct suppression of miR488, an anti-metastatic microRNA; and the downregulation of miR488 subsequently increased the expression of SATB1 and Twist1, which are two major EMT initiators leading to the acquisition of mesenchymal phenotype [81]. Resveratrol inhibit LPS-induced EMT in mouse melanoma through the down-regulation of NF-κB activity [82]. In oral squamous cell carcinoma (OSCC), TAMs play a protumor role and promote EMT through activation of Gas6/Axl-NF-κB [83]. Pterostilbene, a natural stilbene isolated from blueberries, possesses anti-cancer effects in a variety of cancer types [84]. In breast cancer, a recent study demonstrates that pterostilbene effectively suppresses the generation of CSCs and metastatic potential under the influence of M2 TAMs via modulating EMT associated signaling pathways, specifically NFκB/miR488 circuit [85].

Crosstalk between TAMs and TLR4/IL-10

Toll-like receptors (TLRs) play critical roles in innate immunity and are primarily expressed on macrophages and dendritic cells. The activation of TLRs in these cells induce cytokine secretion
Regulation of EMT by TAMs in cancer

TLR4, one of this class of receptors, has been demonstrated closely to the connection between inflammation-mediated carcinogenesis and tumor progression [86]. The inhibition of TLR4 signaling in TAMs reduced cytokines and weakened their tumor-promoting activity in experimental lung metastasis [87]. In human hepatocellular carcinoma, evidence indicated that TLR4/JNK/MAPK signaling was required for LPS-induced EMT [88, 89]. IL-10, a type II cytokine, has been demonstrated to play a critical role in regulating macrophages. It is produced by monocytes, a subtype of dendritic cells, and activated macrophages [90]. Besides, additional sources of IL-10 in cancers include the alternatively activated M2 TAMs [91]. The local production of IL-10 results in a tumor microenvironment favors cancer cells survival and metastases [91-94]. Evidence indicates the activation of TLR4 signaling on M2-polarized TAMs stimulates an increased release of IL-10 [95]. Recently, the potential role of TLR4/IL-10 signaling in the EMT of pancreatic cancer is clarified, M2-polarized TAMs promoted EMT in pancreatic cancer cells partially through TLR4/IL-10 signaling [15].

Crosstalk between TAMs and TGF-β1

Transforming growth factor-β (TGF-β) influences cell differentiation, proliferation, motility, and apoptosis as a multifunctional cytokine [96, 97]. The expression of TGF-β is abundant in chronic inflammatory diseases and cancer [98]. TGF-β1 is one of the most important members of TGF-β. TGF-β1 plays critical roles in cancer progression and metastasis [99, 100], which induces epithelial plasticity leading to EMT in cancer cells [98, 101]. TGF-β1/Smad signaling directly activates the expression of EMT transcription factors, including ZEB1, ZEB2, Snail, Slug and Twist. In breast cancer, evidence shows the Ras effector Blimp-1 play an essential role in TGF-β1-induced EMT via repression of BMP-5 [102]. KLF8 involves in TGF-β1-induced EMT and promotes invasion and migration in gastric cancer cells [98]. MiRNA-200b represses TGF-β1-induced EMT and fibronectin expression in kidney proximal tubular cells [103]. TAMs can induce EMT in intratumoral cancer cells through TGF-β signaling and activation of the β-catenin pathway [104]. Two double-negative feedback loops: one between the transcription factor SNAIL1 and miR-34 family and the other between the transcription factor ZEB1 and miR-200 family, have been found involved in TGF-β1-induced EMT of MCF10A cells [105]. NFκB signalling is involved in TGF-β1-induced EMT [106-108].

A recent study showed that TAMs promote hepatocellular carcinoma CSC-like properties via TGF-β1-induced EMT. Depletion of TGF-β1 blocked acquisition of CSC-like properties through inhibition of TGF-β1-induced EMT [14]. In human cholangiocarcinoma (CCA) cell lines, the various cytokines secreted by TAMs including TGF-β1 induced EMT [109]. Evidence showed that TAMs co-culture enhanced invasion of gastric cancer cells via TGF-β and BMP pathways [110]. These findings provided convincing evidence that there was a tight crosstalk between TAMs and TGF-β1 signaling pathways, and TAMs may play a central role in tumor EMT through interaction with TGF-β1 signaling.

Crosstalk between TAMs and FoxQ1

Forkhead box Q1 (FoxQ1) is a member of the forkhead transcription factor family [111]. FoxQ1 plays critical roles in hair follicle morpho-

<table>
<thead>
<tr>
<th>Table 1. Role of TAMs in cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Role of TAMs in cancer</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>Cancer initiation and promotion</td>
</tr>
<tr>
<td>Cancer angiogenesis</td>
</tr>
<tr>
<td>Cancer invasion and metastasis</td>
</tr>
<tr>
<td>Cancer immunoregulation</td>
</tr>
</tbody>
</table>
Regulation of EMT by TAMs in cancer

Figure 1. A proposed model for TAMs that controls the processes of EMT. TAMs triggers EMT through regulation of TLR4/IL-10, Versican V1, TGF-β1, Gas6/Axl, miR488, FoxQ1 and NFκB.

generation and gastric epithelial differentiation [112]. Evidences from studies demonstrated that increased FoxQ1 expression is correlated with metastasis and poor prognosis for colon cancer, lung cancer, and breast cancer [113-116]. FoxQ1 induces an EMT change, gain of stem cell-like properties, and acquisition of resistance to chemotherapy-induced apoptosis [114]. FoxQ1 represses E-cadherin expression via binding to the E-box in its promoter region, and the knockdown of FoxQ1 blocks TGF-β-induced EMT in breast cancer cells [116]. The suppression of FoxQ1 is implicated in benzyl isothiocyanate-mediated inhibition of EMT in human breast cancer cells [117]. In bladder cancer, it has been demonstrated short hairpin RNA targeting FoxQ1 inhibit invasion and metastasis of cancer cells via the reversal of EMT [118]. In Hela cells, evidence show FoxQ1 promote TGF-β1 expression and induce EMT [119]. In NSCLC, FoxQ1 is implicated in regulating EMT and increasing chemosensitivity, down-regulation of FoxQ1 promotes the expression of epithelial markers, decreases several mesenchymal markers in vitro and in vivo, and increases resistance to conventional chemotherapeutic agents [120]. Versican V1 is an aggregating chondroitin sulfate proteoglycan, which is secreted by both tumor cells and TAMs [121]. It is an important proinflammatory mediator in the tumor microenvironment, and the increased expression of Versican V1 correlates with metastasis and poor survival in many human cancers [122-124]. Recently a study reported FoxQ1 expression is an independent and significant risk factor for hepatocellular carcinoma. FoxQ1 induces EMT via the transactivation of ZEB2 expression by directly binding to the ZEB2 promoter; Versican V1 was identified as a direct transcriptional target of FoxQ1, the inhibition of Versican V1 inhibits FoxQ1-mediated TAMs migration; animal studies show the up-regulation of FoxQ1 in HCC cells promote HCC metastasis and intratumor TAMs infiltration; in human HCC tissues, FoxQ1 expression is positively correlated with ZEB2 and Versican V1 expression and intratumoral TAM infiltration [125]. Taken together, there is a reciprocal interaction between TAMs and FoxQ1 signaling, which may contribute to the development of EMT in cancer.

TAMs as a cancer therapeutic target

Since TAMs plays a critical role in the development and progression of human cancer, it also plays a critical role in the regulation of EMT in cancer. Targeting TAMs could be a novel strategy for the treatment of human cancers. TAMs could be either tumor killing (M1 or activated) or tumor promoting (M2 or alternatively activated) [126, 127]. Large-scale transcriptome analysis results revealed macrophages have a mixed phenotype expressing both M1 and M2 markers [12]. Several recent studies indicated the approach of block macrophage trophic phenotypes together with their immunosuppressive behaviors and enhance their activation, and antitumoral activities is feasible and therapeutic [128, 129]. The major strategy targeting TAMs for cancer therapy based upon genetic experiments is inhibition of CSF-1 signaling by anti-CSF1 receptor-neutralizing antibodies or small-molecule inhibitors [128]. The inhibition of CSF-1R causes TAMs to repolarize to a state regulated by GM-CSF in glioblastoma, cervical and breast cancer models have been demonstrated to be antitumoral [8, 130]. Small-molecule inhibitors to CSF1R could deplete some populations of TAMs and enhance tumor responses to chemotherapy by the removal of macrophage-mediated immunosuppression during the tumor recovery period [33, 131]. Study results showed low-dose irradiation of tumors programs macrophages to an activated state could orchestrate T cell immunotherapy.
Macrophages could also enhance monoclonal antibodies therapeutic efficacy of monoclonal antibodies [129]. Trabectedin could directly kill monocytes and/or macrophages and could be a therapeutic agent against tumors in mice models [133]. Recently a study indicated amphotericin B could enhance macrophage-mediated inhibition of glioma tumor-initiating cells [134]. Striking, using a neutralizing antibody to the CSF1R in a single-molecule approach has been applied in diffuse-type giant cell tumors that overexpress CSF1 in a recent clinical trial [135].

Conclusions and future directions

In conclusion, TAMs play critical roles in the development and progression of human cancer, in which it is mediated through regulation of cancer initiation and promotion, cancer angiogenesis, cancer invasion and metastasis, cancer immunoregulation. EMT plays a fundamental role in tumor progression and metastasis formation by invasion, resistance to cell death and senescence, resistance to chemo-therapy and immunotherapy, immune surveillance, immunosuppression and inflammation, and confers stem cell properties [5]. Accumulated evidences have demonstrated that TAMs plays critical role in the regulation of EMT in cancer [13-16]. This review discussed the role of TAMs in regulation EMT with signaling pathways, including NFκB, TLR4/IL-10, TGF-β1 and FoxQ1 (Figure 1). Therefore, targeting TAMs could be a promising strategy for the treatment of cancers. Therreocent ongoing experimental and pre-clinical TAMs targeted studies have indeed made some encouraging progress. We believe that TAMs targeted strategy will be applied in clinic for cancer patients in the future.

Acknowledgements

This work was supported by the Scientific and Technological Planning project of Shaanxi Province (No. 2014KW23-02) and the Fundamental Research Funds for the Central Universities.

Disclosure of conflict of interest

None.

Address correspondence to: Weimin Li, Department of Nutrition, The First Affiliated Hospital of Xi’an Jiaotong University, 277# West Yanta Road, Xi’an, Shaanxi 710061, China. Tel: 13571999790; E-mail: 760230249@qq.com

References

[14] Fan QM, Jing YY, Yu GF, Kou XR, Ye F, Gao L, Li R, Zhao QD, Yang Y, Lu ZH and Wei LX. Tumor-associated macrophages promote can-


Regulation of EMT by TAMs in cancer


Regulation of EMT by TAMs in cancer


[79] Torroella-Kouri M, Silvera R, Rodriguez D, Caso RA, Shatry A, Opiela S, Ilovitch D, Schwendener PA, Iragavarapu-Charyulu V, Cardentey Y, Strbo N and Lopez DM. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are...
Regulation of EMT by TAMs in cancer


[90] Bernett H, Sekikawa K, Radcliffe RA, Iraqi F, You M and Malkinson AM. Tnfα and Il-10 deficiencies have contrasting effects on lung tu-
Regulation of EMT by TAMs in cancer


Regulation of EMT by TAMs in cancer


